Guangzhou Virotech Pharmaceutical Co., Ltd., a China-based pharmaceutical company, has announced receiving tacit clinical approval from the National Medical Products Administration (NMPA) for its oncolytic virus therapy, M1 (VRT106). This approval paves the way for an imminent Phase I clinical study in China, which will assess the safety, tolerability, pharmacokinetics, and potential efficacy of the drug when administered intravenously to patients with advanced or metastatic solid tumors.
Upcoming Phase I Clinical Study in China
The Phase I clinical study will be a crucial step in evaluating M1 (VRT106) as a treatment option for patients with advanced or metastatic solid tumors. The study will provide valuable insights into the drug’s safety profile, tolerability, and pharmacokinetic behavior, as well as its potential efficacy in combating cancer.
Previous Success in Phase I Trials
Previously, M1 (VRT106) has demonstrated good safety and efficacy in Phase I clinical trials conducted in both China and Japan. These positive results have set a strong foundation for the upcoming trials and have contributed to the optimism surrounding the potential of oncolytic virus therapies in cancer treatment.-Fineline Info & Tech
